Novo Nordisk A/S (CPH:NOVO.B)
265.15
+1.65 (0.63%)
At close: Apr 28, 2026
Novo Nordisk Revenue
In the year 2025, Novo Nordisk had annual revenue of 309.06B DKK with 6.43% growth. Novo Nordisk had revenue of 79.14B in the quarter ending December 31, 2025, a decrease of -7.63%.
Revenue
309.06B
Revenue Growth
+6.43%
P/S Ratio
3.80
Revenue / Employee
4.47M
Employees
69,505
Market Cap
1.18T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 309.06B | 18.66B | 6.43% |
| Dec 31, 2024 | 290.40B | 58.14B | 25.03% |
| Dec 31, 2023 | 232.26B | 55.31B | 31.26% |
| Dec 31, 2022 | 176.95B | 36.15B | 25.68% |
| Dec 31, 2021 | 140.80B | 13.85B | 10.91% |
| Dec 31, 2020 | 126.95B | 4.93B | 4.04% |
| Dec 31, 2019 | 122.02B | 10.19B | 9.11% |
| Dec 31, 2018 | 111.83B | 135.00M | 0.12% |
| Dec 31, 2017 | 111.70B | -84.00M | -0.08% |
| Dec 31, 2016 | 111.78B | 3.85B | 3.57% |
| Dec 31, 2015 | 107.93B | 19.12B | 21.53% |
| Dec 31, 2014 | 88.81B | 5.23B | 6.26% |
| Dec 31, 2013 | 83.57B | 5.55B | 7.11% |
| Dec 31, 2012 | 78.03B | 11.68B | 17.60% |
| Dec 31, 2011 | 66.35B | 5.57B | 9.16% |
| Dec 31, 2010 | 60.78B | 9.70B | 18.99% |
| Dec 31, 2009 | 51.08B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Coloplast | 27.89B |
| H. Lundbeck | 24.63B |
| Genmab | 23.66B |
| Demant | 22.97B |
| GN Store Nord | 16.78B |
| Zealand Pharma | 9.21B |
| ALK-Abelló | 6.31B |
| Bavarian Nordic | 6.24B |
Novo Nordisk News
- 8 hours ago - Health Canada approves first generic version of Novo Nordisk's Ozempic - Reuters
- 17 hours ago - Novo Nordisk to present new data on Wegovy®, women with obesity and next-generation weight loss treatments at European Congress on Obesity - GlobeNewsWire
- 23 hours ago - Boehringer-Zealand drug leads to 16.6% weight loss in late-stage trial - Reuters
- 1 day ago - Novo Nordisk A/S - share repurchase programme - GlobeNewsWire
- 4 days ago - Is It Too Late to Buy Novo Nordisk AS (NVO) After 6.9% Rally? GF Value Says Undervalued - GuruFocus
- 4 days ago - Lilly stock falls as Foundayo trails Novo's Wegovy in early uptake - Invezz
- 4 days ago - Battle Of The Weight-Loss Pills Continues With A Shocking Twist - Investor's Business Daily
- 4 days ago - Novo Nordisk Shares Rise After Positive Oral Semaglutide Trial In Children - Benzinga